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ABSTRACT 
When examining patients with acute inflammatory respiratory diseases, it is difficult to distinguish between infec-
tious pneumonia and interstitial pneumonia and predict patient prognosis at the beginning of treatment. In this 
study, we assessed whether endothelial selectin (E-selectin) predicts the outcome of patients with acute inflamma-
tory respiratory diseases. We measured E-selectin serum levels in 101 patients who were admitted to our respira-
tory care unit between January 2013 and December 2013 because of acute inflammatory respiratory diseases that 
were eventually diagnosed as interstitial pneumonia (n = 38) and lower respiratory tract infection (n = 63). Seven 
of these patients (n = 101) died. The pneumonia severity score was significantly higher and the oxygen saturation 
of arterial blood measured by pulse oximeter (SpO2)/fraction of inspiratory oxygen (FiO2) was significantly lower 
in the deceased patients than in the surviving patients. There were significantly fewer peripheral lymphocytes and 
significantly higher E-selectin serum levels in the deceased patients than in the surviving patients. In the multiple 
logistic regression analysis, the E-selectin serum levels and SpO2/FiO2 ratio were independent predictive factors 
of prognosis. The risk of death during acute respiratory disease was determined using a receiver operating charac-
teristic (ROC) curve analysis. The area under the curve (AUC) was 0.871 as calculated from the ES, and the cutoff 
value was 6453.04 pg/ml, with a sensitivity of 1.00 and a specificity of 0.72 (p = 0.0027). E-selectin may be a 
useful biomarker for predicting the prognosis of patients with acute inflammatory respiratory diseases. 
 
Keywords: Acute inflammatory respiratory disease, infectious pneumonia, interstitial pneumonia, endothelial se-
lectin, prognosis 
 
 
INTRODUCTION 
Despite progress in medical treatments 
such as antibiotic therapy and the develop-
ment of public health, respiratory diseases are 
one of the leading causes of death worldwide 
(Lozano et al., 2013). Pneumonia is a major 
respiratory disease and a life-threatening 
health problem. Moreover, in Japan, more 
than 100,000 people die from pneumonia 
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every year, making it the third leading cause 
of death (Ishiguro et al., 2016). Interstitial 
pneumonia is also a lethal disease. The prog-
nosis of interstitial pneumonia is extremely 
poor. The mortality ratio of acute exacerba-
tion of idiopathic pulmonary fibrosis (IPF), 
the most significant disease among interstitial 
pneumonia, is 80 % (Enomoto et al., 2018; 
Atsumi et al., 2018; Marchioni et al., 2018). 
Moreover, 40 % of patients with IPF die from 
acute exacerbation (Natsuizaka et al., 2014). 
We can evaluate severity and predict the 
prognosis of community-acquired pneumonia 
(CAP) using A-DROP scores established by 
the Japanese Thoracic Society. Patients are 
scored by age, presence of dehydration, pres-
ence of respiratory failure, state of conscious-
ness or orientation, and blood pressure 
(Shindo et al., 2008). However, the A-DROP 
score is not used for evaluating the severity of 
acute exacerbation of interstitial pneumonia. 
Instead, Krebs von den Lungen-6 (KL-6), 
Surfactant protein (SP)-A, and SP-D are ef-
fective biomarkers for evaluating the severity 
and prognosis of interstitial pneumonia 
(Yokoyama et al., 2006; Chiba et al., 2018). 
Clinically, we examine many patients with 
acute respiratory failure such as pneumonia 
and interstitial pneumonia. It can be difficult 
to distinguish between bacterial pneumonia 
and interstitial pneumonia and to predict 
prognosis at the time of admission. Therefore, 
in situations where pneumonia and interstitial 
pneumonia cannot be distinguished, useful bi-
omarkers are necessary to estimate severity 
and prognosis. 
Endothelial selectin (E-selectin) is an ad-
hesion molecule expressed on vascular endo-
thelial cells. Pro-inflammatory cytokines such 
as tumor necrosis factor (TNF)-α or interleu-
kin-1β induce E-selectin (Darveau et al., 
1995). E-selectin is a mediator of leukocyte 
rolling and recruitment during infection. E-se-
lectin plays an important role in the attach-
ment of leukocytes to endothelial cells and the 
accumulation of leukocytes in inflamed tis-
sues during infectious diseases, malignant tu-
mors, and autoimmune diseases (Darveau et 
al., 1995; Benekli et al., 1998; McMurray, 
1996). We demonstrated previously that E-se-
lectin predicts the occurrence of acute lung in-
jury (ALI) in pneumonic patients. E-selectin 
serum levels were elevated in pneumonic pa-
tients with ALI or clinically comparable ALI 
(cALI) (Osaka et al., 2011). We investigated 
whether evaluating the circulating serum E-
selectin levels in patients with severe pneu-
monia can be useful for the prediction of com-
plicating ALI or cALI (Osaka et al., 2011). 
Based on this foundation, we hypothesized 
that E-selectin plays an important role in the 
severity of acute inflammatory respiratory 
diseases such as infectious pneumonia and in-
terstitial pneumonia. In this study, we exam-
ined whether E-selectin is a biomarker for es-
timating the severity and prognosis before dif-
ferential diagnosis in the acute phase of acute 
inflammatory respiratory diseases such as 
pneumonia and interstitial pneumonia. 
 
MATERIAL AND METHODS 
Study population 
We recruited 101 patients admitted to 
Yamagata University Hospital between Janu-
ary 2013 and December 2013 because of 
acute inflammatory respiratory diseases (63 
patients were finally diagnosed with bacterial 
pneumonia and 38 patients were finally diag-
nosed with interstitial pneumonia). Patients 
with chronic obstructive pulmonary disease 
(COPD) exacerbation were excluded because 
non-inflammatory etiologies such as heart 
failure were sometimes associated with exac-
erbation, even in patients with COPD exacer-
bation, because of lower respiratory infection. 
The Institutional Ethics Committee of the 
Yamagata University Faculty of Medicine ap-
proved this study (approval number; H23-
134, approval date Jan. 5th, 2012; H28-221, 
approval date Aug. 29th, 2016). Written in-
formed consent was obtained from all sub-
jects. The severity of CAP was evaluated in 
all patients using the “A-DROP” score (pa-
tient age, presence of dehydration, presence 
of respiratory failure, state of conscious-
ness/orientation, and presence of shock (low 
blood pressure)), established by the Japanese 
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Respiratory Society (Shindo et al., 2008). At 
the time of admission, all patients underwent 
chest Computed tomography (CT) scans for 
the diagnosis of acute inflammatory respira-
tory diseases. Sputum and/or blood cultures 
were performed for the patients from whom 
samples could be obtained. The final diagno-
sis of bacterial pneumonia or interstitial pneu-
monia was performed by multiple respiratory 
physicians with reference to the CT image 
findings, laboratory data including sputum 
and blood bacterial cultures, and clinical 
course. Although all patients received suitable 
treatment according to the final diagnosis, 
seven patients died. 
 
Laboratory data 
Peripheral blood counts, nutritional status 
(as indicated by serum total protein (TP) lev-
els), albumin levels, liver function, renal 
function, inflammatory response (indicated 
by C-reactive protein (CRP) levels), procalci-
tonin (PCT) as a biomarker of bacterial infec-
tion or sepsis, and KL-6 as a biomarker of in-
terstitial pneumonia were measured at the 
time of admission using routine laboratory 
tests. Serum samples were collected simulta-
neously with the blood collection at the time 
of admission and stored in a freezer at −80 °C. 
 
Measurement of E-selectin serum levels 
E-selectin serum concentrations were 
measured with enzyme-linked immuno-
sorbent assay kits (R&D Systems, Minneap-
olis, MN), according to the manufacturer’s 
protocol. 
 
Statistical analyses 
All data were expressed as the mean ± 
standard deviation or the median and 25th to 
75th percentiles. To compare between two 
groups, the Mann-Whitney U test or the Chi-
squared test were conducted. Risk factors for 
death were detected by univariate and multi-
variate logistic regression analyses. We used 
a receiver operating characteristic (ROC) 
curve to determine the cutoff value for E-se-
lectin serum levels in detecting the risk of 
death in patients with acute inflammatory res-
piratory diseases. All statistical analyses were 
performed with JMP software, version 11.0.0 
(SAS Institute Inc., Cary, NC, USA), and p < 
0.05 was considered statistically significant. 
 
RESULTS 
Table 1 summarizes comparisons of the 
patient profiles, illness severity according to 
A-DROP score, oxygenation, and laboratory 
data between the surviving patients and de-
ceased patients. There were no significant dif-
ferences in age, sex, peripheral white blood 
cell numbers, nutrition status, liver function, 
or renal function between the surviving pa-
tients and deceased patients. More of the pa-
tients who died had required oxygen supple-
mentation. Lower SpO2/FiO2 levels and 
higher A-DROP scores were reported in the 
deceased patients compared to the surviving 
patients. Furthermore, there were signifi-
cantly fewer peripheral lymphocytes in the 
deceased patients than in the surviving pa-
tients. Although the inflammatory responses 
such as CRP, PCT, and KL-6 serum levels did 
not differ between the two groups, the E-se-
lectin serum levels were significantly higher 
in the deceased patients than in the surviving 
patients. 
The univariate logistic regression analysis 
was used to evaluate the risk of death in pa-
tients with acute inflammatory respiratory 
diseases. Fewer peripheral blood lympho-
cytes, higher E-selectin serum levels, lower 
SpO2/FiO2 ratios, and higher A-DROP scores 
were significant predictive factors for death 
(Table 2). 
In the multiple logistic regression analy-
sis, a lower SpO2/FiO2 ratio and a higher E-
selectin serum level were significant risk fac-
tors for predicting death even when adjusted 
for age, sex, peripheral lymphocyte number, 
and illness severity (Table 3). 
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Table 1: Profiles of patients and data, comparison of deceased and non-deceased patients 
  All patients Non-deceased Deceased p value 
  (n=101) (n=94) (n=7)   
Age, years 75 (68 – 83) 75 (68 – 83) 77 (67 – 84) 0.9840  
Sex, M/F 63/38 57/37 6/1 0.1864  
Infectious pneumonia/ 
Interstitial pneumonia 63/38 59/35 4/3 0.7670  
A-DROP score  
0 / 1 / 2 / 3 / 4 11 / 25 / 41 / 19 / 4 / 1 11 / 22 / 41 / 15 / 4 / 1 0 / 3 / 0 / 4 / 0 / 0  0.0491* 
Use of supplemental  
oxygen, % 44.6 41.4 85.7 0.0010* 
SpO2/FIO2 419.0 (296.9 - 452.4) 428.6 (302.3 - 453.6) 158.3 (96.0 - 357.1) 0.0070* 
TP, g/dl 6.4 ± 0.8 6.4 ± 0.8 6.4 ± 0.7 0.8339  
Alb, g/dl 3.1 ± 0.6 3.1 ± 0.6 2.6 ± 0.7 0.1246  
AST, U/l 22 (17 - 32) 22 (17 – 31) 24 (20 – 36) 0.4780  
ALT, U/l 16 (11- 25) 17 (11 – 25) 15 (10 – 27) 0.6016  
LDH, U/l 221 (184 - 291) 219 (181 – 287) 266 (215 – 413) 0.0870  
BUN, mg/dl 15 (12 - 20) 15 (12 – 20) 16 (11 – 50) 0.5287  
Cre, mg/dl 0.67 (0.52 - 0.86) 0.68 (0.52 – 0.85) 0.63 (0.55 - 2.01) 0.8672  
eGFR, ml/min 80.6 (60.1 - 101.2) 79.9 (60.2 – 101.6) 84.4  (25.3 - 100.3) 0.9012  
Na, mEq/l 140 (138 - 142) 140 (138 – 142) 140 (135 – 145) 0.6872  
K, mEq/l 4.04 ± 0.48 4.04 ± 0.48 3.96 ± 0.55 0.5641  
Cl, mEq/l 102.6 ± 5.0 102.7 ± 4.8 100.6 ± 7.1 0.6871  
CRP, mg/dl 7.57 (2.36 - 14.55) 6.85 (1.98 – 13.85 17.66 (8.71 - 25.25) 0.0559  
PCT, ng/ml 0.27 (0.08 - 1.56) 0.27 (0.08 – 1.54) 0.47 (0.10 - 3.39) 0.6086  
KL-6, U/ml 408 (219 - 812) 395  (210 – 803) 500  (319 – 895) 0.3073  
E-Selectin, pg/ml 4595 (2527 - 7802) 4490 (2408 – 6870) 9604 (8823 - 12955) 0.0011* 
Log E-selectin 3.66 (3.40 - 3.89) 3.65 (3.38 – 3.84) 3.98 (3.95 - 4.11) 0.0011* 
WBC, 103/μl 8.11 (6.17 - 11.46) 8.08 (6.04 – 11.43) 8.58 (7.12 - 11.56) 0.4147  
  Neutrophil, 103/μl 6.21 (4.29 - 9.53) 6.12 (4.23 - 9.51) 8.25 (6.69 - 9.65) 0.1297  
  Lymphocyte, 103/μl 1.03 (0.76 - 1.47) 1.06 (0.77 - 1.51) 0.76 (0.18 - 1.08) 0.0406* 
  Monocyte, 103/μl 0.47 (0.31 - 0.66) 0.48 (0.31 - 0.68) 0.38 (0.08 - 0.51) 0.1517  
RBC, 104/μl 389 ± 50.9 389 ± 51.4 389 ± 47.3 0.9467  
Hb, g/dl 11.8 ± 1.8 11.7 ± 1.9 12.2 ± 1.6 0.5652  
Ht, % 36.0 ± 5.0 35.8 ± 5.0 38.1 ± 5.6 0.3290  
Plt, 104/μl 20.8 ± 0.8 20.8 ± 0.8 19.8 ± 10.7 0.7281  
A-DROP score: evaluation of severity of community acquired pneumonia (patient age, presence of de-
hydration, presence of respiratory failure, state of consciousness/orientation, and presence of shock 
(low blood pressure)) 
All data were expressed as the mean ± standard deviation or the median and 25th to 75th percentiles.  
To compare between deceased and non-deceased groups, the Mann-Whitney U test or the Chi-squared 
test were conducted.  
p < 0.05 was considered statistically significant. 
 
 
We plotted a ROC curve to detect the E-
selectin cutoff value for predicting death in 
patients with acute inflammatory respiratory 
diseases (Figure 1). The area under the curve 
(AUC) was 0.87, and the cutoff value was 
6453.04 pg/ml, with a sensitivity of 1.00 and 
a specificity of 0.72 (p = 0.0027). Positive 
predictive value was 0.1875, and negative 
predictive value was 0.9855.
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Table 2: Univariate logistic regression analysis investigating potential risk factors associated with poor 
prognosis in patients with acute inflammatory respiratory diseases 
  OR 95% CI P value 
Age, years 1.054  0.507 -2.520 0.8943  
Sex, male 3.895  0.630 - 75.094 0.1576  
Lymphocyte 0.280  0.071 - 0.806 0.0150* 
Log e-selectin 7.837  2.151 - 43.781 0.0006* 
SpO2/FIO2 0.297  0.120 - 0.615 0.0009* 
A-DROP score > 2  4.933  1.011 - 26.789 0.0485* 
Age, Lymphocyte, Log e-selectin, SpO2/FiO2 : +1 standard deviation 
p < 0.05 was considered statistically significant. 
 
 
 
Figure 1: ROC curve to detect an E-selectin cutoff value for predicting death in patients with acute 
inflammatory respiratory diseases. The area under the curve (AUC) was 0.87, and the cutoff value was 
6453.04 pg/ml, with a sensitivity of 1.00 and a specificity of 0.72 (p = 0.0027). Positive predictive value 
(PPV) was 0.1875, and negative predictive value (NPV) was 0.9855.  
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Table 3: Multivariate logistic regression analysis investigating potential risk factors associated with poor 
prognosis in patients with acute inflammatory respiratory diseases 
  OR 95% CI P value 
Age, years 1.202  0.366 - 4.301 0.7630  
Sex, male 4.240  0.438 - 110.746 0.2309  
Lymphocyte 0.703  0.179 - 2.059 0.5372  
Log e-selectin 4.976  1.253 - 36.410 0.0182* 
SpO2/FIO2  0.366  0.113 - 0.964 0.0418* 
A-DROP score > 2  1.678  0.153 - 20.013 0.6640  
Age, Lymphocyte, Log e-selectin, SpO2/FiO2 : +1 standard deviation 
 
 
DISCUSSION 
In this study, we investigated whether E-
selectin serum levels can serve as an inde-
pendent predictive marker for the prognosis 
of patients with acute inflammatory respira-
tory diseases, including infectious pneumonia 
and interstitial pneumonia. Various factors 
predicting prognosis for infectious pneumo-
nia or interstitial pneumonia have been inves-
tigated in previous studies, and several bi-
omarkers have been established as predictors 
of prognosis for each disease (Shindo et al., 
2008; Chalmers et al., 2010; Zhang et al., 
2018; Wang et al., 2017; Gwak et al., 2015). 
For example, the A-DROP score is a well-
known evaluation system to predict the sever-
ity and prognosis of CAP in Japan (Shindo et 
al., 2008). In addition to the A-DROP score, 
CURB65 and the pneumonia severity index 
(PSI) are also similar evaluation systems 
(Chalmers et al., 2010; Zhang et al., 2018). 
Recently, a combination of data including re-
nal function, white blood cell count, CRP lev-
els, and serum HCO3- was an independent 
predictive factor for hospital mortality (Wang 
et al., 2017). The serum lactate level was re-
ported to be associated with inpatient mortal-
ity in patients with CAP (Gwak et al., 2015). 
KL-6 is a good predictive marker for the prog-
nosis of interstitial pneumonia (Yokoyama et 
al., 2006). The serum ferritin level has a good 
prognostic value in patients with acute exac-
erbation of IPF, which is the most common 
type of idiopathic interstitial pneumonia 
(Enomoto et al., 2018). The gender-age-phys-
iology (GAP) index, composed of sex, age, 
and respiratory function, is known to predict 
the prognosis of interstitial pneumonia 
(Atsumi et al., 2018). Based on these findings, 
many factors have been reported to predict the 
prognosis of each disease, but few factors are 
common predictors of both diseases. There-
fore, pulmonary physicians must correctly 
differentiate and diagnose infectious pneumo-
nia and interstitial pneumonia to utilize appro-
priate biomarkers and select the best treat-
ment for these diseases. In the initial exami-
nation of patients with respiratory diseases, 
thoracic radiographic imaging such as chest 
X-ray and chest CT scan and blood sampling 
tests are usually performed. We can make a 
differential diagnosis if typical radiographic 
imaging or laboratory data findings are ob-
served. However, clinically, it is sometimes 
difficult to distinguish between infectious 
pneumonia and interstitial pneumonia if typi-
cal findings are not present. Pulmonary phy-
sicians must make a diagnosis and initiate 
treatment for patients with acute inflamma-
tory respiratory diseases even when lacking 
sufficient information for a correct diagnosis. 
Based on these findings, identifying common 
biomarkers between infectious pneumonia 
and interstitial pneumonia that can estimate 
prognosis is necessary. 
In this study, a lower SpO2/FiO2 ratio was 
also an independent predictive marker for 
EXCLI Journal 2019;18:1062-1070 – ISSN 1611-2156 
Received: July 09, 2019, accepted: November 04, 2019, published: November 11, 2019 
 
 
1068 
prognosis in patients with acute inflammatory 
respiratory diseases. The presence of respira-
tory failure is the one of the evaluation values 
in the A-DROP score and CURB-65 score. 
However, SpO2 tends to fluctuate depending 
on measurement conditions. Therefore, E-se-
lectin may be a more accurate biomarker to 
predict prognosis in patients with acute in-
flammatory respiratory diseases than the 
SpO2 value even though the measured SpO2 
value can be determined immediately. 
Osaka et al. investigated whether circulat-
ing levels of E-selectin were elevated in pneu-
monic patients with ALI or cALI. The meas-
urement of E-selectin serum levels in patients 
with severe pneumonia may be useful for dis-
criminating between complicating ALI or 
cALI (Osaka et al., 2011). This study showed 
that E-selectin is a more effective biomarker 
for predicting the onset of ALI than white 
blood cell count, CRP, and LDH, which have 
been well-known biomarkers for a long time. 
Moreover, circulating levels of soluble E-se-
lectin are elevated in patients with sepsis and 
shock (Kayal et al., 1998; Newman et al., 
1993; Reinhart et al., 2002). Additionally, hy-
poxia is more common in patients with high 
soluble E-selectin levels and systemic inflam-
matory response syndrome (SIRS) compared 
to patients with normal E-selectin levels and 
SIRS (Okajima et al., 2006). In our study, we 
showed that the serum E-selectin level is an 
independent predictor of prognosis in patients 
with acute respiratory disease, including in-
fectious pneumonia and interstitial pneumo-
nia. Even in cases in which pulmonary physi-
cians cannot determine whether the patient 
has bacterial or interstitial pneumonia at the 
time of admission, it is worthwhile to predict 
their prognosis using a single factor, E-selec-
tin. 
This study has several limitations. We ret-
rospectively performed this study at a single 
institute, and the study size was fairly small. 
All patients with interstitial pneumonia were 
clinically diagnosed by laboratory data, such 
as the KL-6 level, and radiological findings, 
such as chest X-ray and chest CT scan; patho-
logical findings were not used for diagnosis. 
E-selectin was only measured once during 
days one to four. The time courses of E-selec-
tin levels were not evaluated. Information re-
garding the long-term prognosis throughout 
the hospitalization period was not available. 
Further investigation will be necessary to so-
lidify the clinical significance of E-selectin in 
acute respiratory disease by evaluating the 
time course of E-selectin. 
 
CONCLUSIONS 
In conclusion, we demonstrated that E-se-
lectin is an independent predictive factor for 
death from acute respiratory diseases includ-
ing infectious and interstitial pneumonia. 
These results suggest that E-selectin might be 
a useful biomarker for predicting the progno-
sis of patients with acute respiratory diseases, 
even in situations in which pulmonary physi-
cians cannot determine whether the patient 
has bacterial or interstitial pneumonia. 
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